Progress in research on screening and genetics in lung cancer

Fred R. Hirsch; Paul A. Bunn

doi:10.1016/S2213-2600(13)70264-9

Progress in research on screening and genetics in lung cancer

Fred R. Hirsch, Paul A. Bunn

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Original language	English
Pages (from-to)	19-21
Number of pages	3
Journal	The Lancet Respiratory Medicine
Volume	2
Issue number	1
DOIs	https://doi.org/10.1016/S2213-2600(13)70264-9
State	Published - Jan 2014
Externally published	Yes

Access to Document

10.1016/S2213-2600(13)70264-9

Cite this

@article{39073382331441199eb5fffe161dc9ff,

title = "Progress in research on screening and genetics in lung cancer",

author = "Hirsch, {Fred R.} and Bunn, {Paul A.}",

note = "Funding Information: FRH has been a consultant and served on advisory boards for Roche/Genentech, Pfizer, Lilly, Boehringer-Ingelheim, Celgene, Novartis, Amgen, and Synta; and has received research grants (through the University of Colorado) from Ventana, Lilly/Imclone, Celgene, and Amgen. PAB has been a consultant and served on advisory boards for Amgen, Astellas, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Celgene, Daichi Sankyo, Eisai, GlaxoSmithKline, Lilly, Merck, Merck Serono, Myriad, Pfizer, Roche/Genentech, Sanofi, and Synta.",

year = "2014",

month = jan,

doi = "10.1016/S2213-2600(13)70264-9",

language = "English",

volume = "2",

pages = "19--21",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Ltd.",

number = "1",

}

TY - JOUR

T1 - Progress in research on screening and genetics in lung cancer

AU - Hirsch, Fred R.

AU - Bunn, Paul A.

N1 - Funding Information: FRH has been a consultant and served on advisory boards for Roche/Genentech, Pfizer, Lilly, Boehringer-Ingelheim, Celgene, Novartis, Amgen, and Synta; and has received research grants (through the University of Colorado) from Ventana, Lilly/Imclone, Celgene, and Amgen. PAB has been a consultant and served on advisory boards for Amgen, Astellas, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Celgene, Daichi Sankyo, Eisai, GlaxoSmithKline, Lilly, Merck, Merck Serono, Myriad, Pfizer, Roche/Genentech, Sanofi, and Synta.

PY - 2014/1

Y1 - 2014/1

UR - http://www.scopus.com/inward/record.url?scp=84891372198&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(13)70264-9

DO - 10.1016/S2213-2600(13)70264-9

M3 - Comment/debate

C2 - 24461890

AN - SCOPUS:84891372198

SN - 2213-2600

VL - 2

SP - 19

EP - 21

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 1

ER -